Prevalence and Risk Factors of Chemotherapy‐Induced Oral Mucositis in 470 Children With Acute Lymphoblastic Leukemia
International Journal of Paediatric Dentistry · 2025
DOI: 10.1111/ipd.13303 ↗At a glance
Journal article in International Journal of Paediatric Dentistry, 2025. Written by Xiaofeng He and 9 co-authors. Institution: Southern Medical University, School of Nursing, Guang Dong, China. Major MEDLINE topics: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Stomatitis, Antineoplastic Agents. Cited 4 times so far (Crossref); 35 references. Funded by: Key Laboratory of Philosophy and Social Sciences of Colleges and Universities in Guangdong Province for Collaborative Innovation of Health Management Policy an…, Sanming Project of Medicine in Shenzen Municipality.
Topics: Onkologische Pflege, Kinderkrankenpflege
Abstract (original language)
Objective
To assess the prevalence and risk factors of chemotherapy‐induced oral mucositis in 470 children with acute lymphoblastic leukemia in China, focusing on treatment‐related risk factors.
Methods
This cross‐sectional study included 470 children diagnosed with acute lymphoblastic leukemia in China from January 2020 to July 2022. Data were collected from electronic medical records, field investigations, and telephone follow‐ups, covering sociodemographic characteristics, nutritional status, disease and treatment history, and microbiological factors. Univariate and multivariate logistic analyses were used to evaluate the association between the occurrence and severity of chemotherapy‐induced oral mucositis and these variables.
Results
The prevalence of chemotherapy‐induced oral mucositis was 45.1%. Significant risk factors included receiving more than five chemotherapy cycles ( p < 0.001), carrying HSV‐1 ( p = 0.016), infection with Candida albicans ( p = 0.012), undergoing chemotherapy with specific drugs containing methotrexate/daunorubicin/cytarabine ( p < 0.001), having a high clinical risk stratification ( p = 0.002), and being over 6 years old ( p = 0.002). The severity of chemotherapy‐induced oral mucositis was associated with consolidation and intensification period ( p = 0.001) and B‐cell immune stratification ( p < 0.001).
Conclusion
The prevalence of chemotherapy‐induced oral mucositis in children with acute lymphoblastic leukemia is relatively high. It emphasizes the importance of clinical medical staff paying attention to this issue and adopting targeted interventions to reduce the prevalence of oral mucositis in this patient population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Southern Medical University, School of Nursing, Guang Dong, China.
- The First Affiliated Hospital of University of South China, Hu Nan, China.
- Department of Pediatric, Zhu Jiang Hospital, Southern Medical University, Guang Dong, China.
ORCID profiles: Xinwen Rong
Funding
- Key Laboratory of Philosophy and Social Sciences of Colleges and Universities in Guangdong Province for Collaborative Innovation of Health Management Policy an…
- Sanming Project of Medicine in Shenzen Municipality
Cite
APA
He, X., Rong, X., Wang, W., Liang, L., Liao, X., Huang, J., Zhang, J., Zhu, W., Liu, W., & Shi, L. (2025). Prevalence and Risk Factors of Chemotherapy‐Induced Oral Mucositis in 470 Children With Acute Lymphoblastic Leukemia. International Journal of Paediatric Dentistry. https://doi.org/10.1111/ipd.13303
Vancouver
He X, Rong X, Wang W, Liang L, Liao X, Huang J, et al. Prevalence and Risk Factors of Chemotherapy‐Induced Oral Mucositis in 470 Children With Acute Lymphoblastic Leukemia. International Journal of Paediatric Dentistry. 2025. doi:10.1111/ipd.13303
BibTeX
@article{He2025,
author = {He, Xiaofeng and Rong, Xinwen and Wang, Weijie and Liang, Lichan and Liao, Xiaomei and Huang, Jiaying and Zhang, Jing and Zhu, Wenting and Liu, Weifei and Shi, Lei},
title = {Prevalence and Risk Factors of Chemotherapy‐Induced Oral Mucositis in 470 Children With Acute Lymphoblastic Leukemia},
journal = {International Journal of Paediatric Dentistry},
year = {2025},
doi = {10.1111/ipd.13303}
}
EUVIMED